I said Phase 1 trials are always focused on safety and that safety is always a primary endpoint. I didn't say anything about it being the only endpoint. If you reread the thread, I make that pretty clear. In fact, my discussion yesterday was to make that same point you make, that there is strong evidence of efficacy, and that one efficacy endpoint for Kevetrin was evidence of p53 modulation.